Viatris Innovation

Part of Viatris

CompanyUnited States

Viatris Innovation develops one asset, in phase 3 (selatogrel in acute myocardial infarction). Mostly small molecule acting on P2RY12; based in the United States.

1
Asset
Furthest stage
Phase 3
6
Trials
0
Signals

Pipeline

1
  • selatogrel

    P2Y12 platelet receptor antagonist inhibiting platelet aggregation

    Phase 3, Small molecule, P2RY12, acute myocardial infarction, chronic coronary syndrome (Phase 1)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials6
  • Signals1
  • Similar companies6

Intelligence